ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 67 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,673,238 | -37.6% | 232,963 | -12.2% | 0.00% | 0.0% |
Q2 2023 | $7,489,304 | +45.0% | 265,484 | -11.6% | 0.00% | 0.0% |
Q1 2023 | $5,164,988 | +6.7% | 300,290 | +24.9% | 0.00% | 0.0% |
Q4 2022 | $4,840,447 | +83.0% | 240,340 | +96.8% | 0.00% | – |
Q3 2022 | $2,645,000 | -69.6% | 122,135 | -60.5% | 0.00% | -100.0% |
Q2 2022 | $8,696,000 | -33.7% | 309,467 | +8.9% | 0.00% | 0.0% |
Q1 2022 | $13,115,000 | -21.0% | 284,248 | +44.0% | 0.00% | -50.0% |
Q4 2021 | $16,592,000 | +195.2% | 197,389 | +134.0% | 0.00% | +100.0% |
Q3 2021 | $5,621,000 | +29.1% | 84,351 | +3.1% | 0.00% | – |
Q2 2021 | $4,353,000 | +10.8% | 81,827 | -9.6% | 0.00% | – |
Q1 2021 | $3,929,000 | +57.4% | 90,542 | +88.4% | 0.00% | – |
Q4 2020 | $2,496,000 | +155.0% | 48,064 | +60.6% | 0.00% | – |
Q3 2020 | $979,000 | +20.3% | 29,932 | +76.7% | 0.00% | – |
Q2 2020 | $814,000 | – | 16,939 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 1,824,583 | $39,520,000 | 14.33% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,301,771 | $49,857,000 | 4.79% |
Matrix Capital Management Company, LP | 9,199,973 | $199,271,000 | 3.81% |
Integral Health Asset Management, LLC | 550,000 | $11,913,000 | 2.31% |
Avidity Partners Management LP | 4,223,100 | $91,472,000 | 1.86% |
Affinity Asset Advisors, LLC | 170,000 | $3,682,000 | 1.03% |
Eventide Asset Management | 1,861,000 | $40,309,000 | 0.79% |
Sofinnova Investments, Inc. | 583,357 | $12,636,000 | 0.74% |
Nicholas Investment Partners, LP | 158,704 | $3,438,000 | 0.32% |
SECTORAL ASSET MANAGEMENT INC | 60,000 | $1,300,000 | 0.26% |